Current management: Management of rheumatic diseases in the era of biological anti-rheumatic drugs

Acta Orthop. 2005 Oct;76(5):614-9. doi: 10.1080/17453670510041673.
No abstract available

Publication types

  • Review

MeSH terms

  • Adalimumab
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / complications
  • Arthritis, Rheumatoid / diagnosis
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / microbiology
  • Drug Therapy, Combination
  • Etanercept
  • Humans
  • Immunoglobulin G / therapeutic use
  • Infliximab
  • Interleukin 1 Receptor Antagonist Protein
  • Opportunistic Infections / complications
  • Opportunistic Infections / drug therapy
  • Practice Guidelines as Topic
  • Receptors, Tumor Necrosis Factor / therapeutic use
  • Sialoglycoproteins / therapeutic use

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • IL1RN protein, human
  • Immunoglobulin G
  • Interleukin 1 Receptor Antagonist Protein
  • Receptors, Tumor Necrosis Factor
  • Sialoglycoproteins
  • Infliximab
  • Adalimumab
  • Etanercept